DALBAVANCIN HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Unknown
Molecule Category: Salt
UNII: 33WDQ7T81E
Parent Compound: DALBAVANCIN

Structure
InChI Key PEXPCJWLNBNBNT-AXKGEONOSA-N
Smile CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O.Cl
InChI
InChI=1S/C88H100Cl2N10O28.ClH/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39;/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121);1H/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C88H101Cl3N10O28
Molecular Weight 1853.18
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Peptidoglycan inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
17.14
Skin and subcutaneous tissue disorders
15.91
Injury, poisoning and procedural complications
14.38
Immune system disorders
9.56
Respiratory, thoracic and mediastinal disorders
7.19
Cardiac disorders
5.81
Musculoskeletal and connective tissue disorders
4.9
Gastrointestinal disorders
4.59
Vascular disorders
4.51
Infections and infestations
2.98
Nervous system disorders
2.98
Psychiatric disorders
2.68
Renal and urinary disorders
2.52
Investigations
2.14

Cross References

Resources Reference
ChEMBL CHEMBL3301650
FDA SRS 33WDQ7T81E
CONTENTS